Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID‐19

Abstract

Malaria is a threat to human mankind and kills about half a million people every year. On the other hand, COVID‐19 resulted in several hundred thousand deaths since December 2019 and remains without an efficient and safe treatment. The antimalarials chloroquine (CQ) and its analog, hydroxychloroquine (HCQ), have been tested for COVID‐19 treatment, and several conflicting evidence has been obtained. Therefore, the aim of this review was to summarize the evidence regarding action mechanisms of these compounds against Plasmodium and SARS‐CoV‐2 infection, together with cytometry applications. CQ and HCQ act on the renin angiotensin system, with possible implications on the cardiorespiratory system. In this context, flow and image cytometry emerge as powerful technologies to investigate the mechanism of therapeutic candidates, as well as for the identification of the immune response and prognostics of disease severity. Data from the large randomized trials support the conclusion that CQ and HCQ do not provide any clinical improvements in disease severity and progression of SARS‐CoV‐2 patients, as well as they do not present any solid evidence of increased serious side effects. These drugs are safe and effective antimalarials agents, but in SARS‐CoV‐2 patients, they need further studies in the context of clinical trials. © 2020 International Society for Advancement of Cytometry

Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology

“…Importantly, the P2X7 receptor triggers pathways related to the functioning of the RAAS, importantly implicated in COVID-19 pathology. RAAS mediates key events of the disease, including viral entry in the cell [ 112 , 113 ], inflammation, and lung fibrosis [ 114 ]. The pressor axis of RAAS bases on Ang II actions through the activation of AT 1 R. ACE is responsible for the cleavage of angiotensin I into Ang II, and Ang II levels are counterbalanced by the depressor axis that degrades Ang II into Ang 1,7 through ACE2 activity.…”

Implications of SARS-Cov-2 infection on eNOS and iNOS activity: Consequences for the respiratory and vascular systems

“…The diffuse inflammation causes pulmonary physiology damage, and also endothelial disfunction and disturbances in nitric oxide (NO) metabolism, which activate coagulation and thrombin generation leading to thrombosis and pulmonary embolism observed in severe COVID-19 patients [ 14 ]. Attempting to find an immediate solution for COVID-19, approved drugs by the Food and Drug Administration (FDA) and similar agencies to treat other diseases are being investigated [ [15] , [16] , [17] ]. Nevertheless, there is no effective treatment for COVID-19, the strategies are to try minimizing the chances of hospitalization in the intensive care unit and to avoid invasive procedures like extracorporeal membrane oxygenation (ECMO) to oxygenate the lungs [ 17 ].…”

G6PD deficiency, redox homeostasis, and viral infections: implications for SARS-CoV-2 (COVID-19)

“…Chloroquine (CQ), a 4-aminoquinoline drug, is commonly used in the treatment of malaria and amoebiasis [122,123]. It is also used for treating autoimmune diseases, including lupus erythematosus and rheumatoid arthritis, due to its capacity for modulating inflammation and the immune response [124,125].…”